Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity.

Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, Hurtado MD, Acosta A

JAMA network open1 Sept 2022Cited by 174 (Europe PMC)

PMID36121652PMCIDPMC9486455DOI10.1001/jamanetworkopen.2022.31982PepBankPUB-36121652

Summary

ImportanceNo retrospective cohort study has assessed the effectiveness of semaglutide at doses used in randomized clinical trials to treat obesity (ie, 1.7 and 2.4 mg).ObjectiveTo study weight loss outcomes associated with semaglutide treatment at doses used in randomized clinical trials for patients with overweight or obesity.Design, setting, and participantsThis cohort study, conducted at a referral center for weight management, retrospectively collected data on the use of semaglutide for adults with overweight or obesity between January 1, 2021, and March 15, 2022, with a follow-up of up to 6 months. A total of 408 patients with a body mass index (BMI) of 27 or more were prescribed weekly semaglutide subcutaneous injections for 3 months or more. Patients with a history of bariatric procedures, taking other antiobesity medications, and with an active malignant neoplasm were excluded.ExposuresWeekly 1.7-mg or 2.4-mg semaglutide subcutaneous injections for 3 to 6 months.Main outcomes and measuresThe primary end point was the percentage of weight loss. Secondary end points were the proportion of patients achieving weight loss of 5% or more, 10% or more, 15% or more, and 20% or more after 3 and 6 months and the percentage of weight loss for patients with or without type 2 diabetes after 3 and 6 months.ResultsThe study included 175 patients (132 women [75.4%]; mean [SD] age, 49.3 [12.5] years; mean [SD] BMI, 41.3 [9.1]) in the analysis at 3 months and 102 patients at 6 months. The mean (SD) weight loss after 3 months was 6.7 (4.4) kg, equivalent to a mean (SD) weight loss of 5.9% (3.7%) (P < .001), and the mean (SD) weight loss after 6 months was 12.3 (6.6) kg, equivalent to a mean (SD) weight loss of 10.9% (5.8%) (P < .001 from baseline). Of the 102 patients who were followed up at 6 months, 89 (87.3%) achieved weight loss of 5% or more, 56 (54.9%) achieved weight loss of 10% or more, 24 (23.5%) achieved weight loss of 15% or more, and 8 (7.8%) achieved weight loss of 20% or more. Patients with type 2 diabetes had a lower mean (SD) percentage weight loss at 3 and 6 months compared with those without type 2 diabetes: 3.9% (3.1%) vs 6.3% (3.7%) at 3 months (P = .001) and 7.2% (6.3%) vs 11.8% (5.3%) at 6 months (P = .005).Conclusions and relevanceThe results of this cohort study suggest that weekly 1.7-mg and 2.4-mg doses of semaglutide were associated with weight loss similar to that seen in randomized clinical trials. Studies with longer periods of follow-up are needed to evaluate prolonged weight loss outcomes.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanObservational studyEfficacy outcome
In adults with overweight or obesity, semaglutide at 1.7 or 2.4 mg weekly was associated with a mean weight loss of 5.9% after 3 months.
In plain wordsIn adults with overweight or obesity, people on semaglutide lost on average 5.9% of body weight after 3 months.
Peptide
Semaglutide
Outcome
DecreaseWeight loss after 3 months
Study
n = 175
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.7 mg or 2.4 mg weekly · subcutaneous · 3 monthsAs given in this study (human).
Measurements
Weight loss
6.7 kg
3 months
Weight loss
5.9%
3 months
Source sentences
Summary
The mean (SD) weight loss after 3 months was 6.7 (4.4) kg, equivalent to a mean (SD) weight loss of 5.9% (3.7%) (P < .001)
2 context sentences(design, population, supporting numbers)
Summary · context
This cohort study, conducted at a referral center for weight management, retrospectively collected data on the use of semaglutide for adults with overweight or obesity between January 1, 2021, and March 15, 2022, with a follow-up of up to 6 months.
Summary · context
A total of 408 patients with a body mass index (BMI) of 27 or more were prescribed weekly semaglutide subcutaneous injections for 3 months or more.
Show in the study text Report a problemFND-3612165201
02HumanObservational studyEfficacy outcome
In adults with overweight or obesity, semaglutide at 1.7 or 2.4 mg weekly was associated with a mean weight loss of 10.9% after 6 months.
In plain wordsIn adults with overweight or obesity, people on semaglutide lost on average 10.9% of body weight after 6 months.
Peptide
Semaglutide
Outcome
DecreaseWeight loss after 6 months
Study
n = 102
Analysis
Primary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.7 mg or 2.4 mg weekly · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Weight loss
12.3 kg
6 months
Weight loss
10.9%
6 months
Source sentences
Summary
the mean (SD) weight loss after 6 months was 12.3 (6.6) kg, equivalent to a mean (SD) weight loss of 10.9% (5.8%) (P < .001 from baseline)
2 context sentences(design, population, supporting numbers)
Summary · context
This cohort study, conducted at a referral center for weight management, retrospectively collected data on the use of semaglutide for adults with overweight or obesity between January 1, 2021, and March 15, 2022, with a follow-up of up to 6 months.
Summary · context
A total of 408 patients with a body mass index (BMI) of 27 or more were prescribed weekly semaglutide subcutaneous injections for 3 months or more.
Show in the study text Report a problemFND-3612165202
03HumanObservational studyEfficacy outcome
In adults with overweight or obesity followed for 6 months on semaglutide, 87.3% achieved weight loss of 5% or more.
In plain wordsIn adults with overweight or obesity, most people on semaglutide (87.3%) lost at least 5% of body weight after 6 months.
Peptide
Semaglutide
Outcome
Not applicableWeight loss of 5% or more at 6 months
Study
n = 102
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.7 mg or 2.4 mg weekly · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Patients with weight loss >=5%
87.3%
6 months
Source sentences
Summary
89 (87.3%) achieved weight loss of 5% or more,
2 context sentences(design, population, supporting numbers)
Summary · context
This cohort study, conducted at a referral center for weight management, retrospectively collected data on the use of semaglutide for adults with overweight or obesity between January 1, 2021, and March 15, 2022, with a follow-up of up to 6 months.
Summary · context
A total of 408 patients with a body mass index (BMI) of 27 or more were prescribed weekly semaglutide subcutaneous injections for 3 months or more.
Show in the study text Report a problemFND-3612165203
04HumanObservational studyEfficacy outcome
In adults with overweight or obesity followed for 6 months on semaglutide, 54.9% achieved weight loss of 10% or more.
In plain wordsIn adults with overweight or obesity, about half of people on semaglutide (54.9%) lost at least 10% of body weight after 6 months.
Peptide
Semaglutide
Outcome
Not applicableWeight loss of 10% or more at 6 months
Study
n = 102
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.7 mg or 2.4 mg weekly · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Patients with weight loss >=10%
54.9%
6 months
Source sentences
Summary
56 (54.9%) achieved weight loss of 10% or more,
2 context sentences(design, population, supporting numbers)
Summary · context
This cohort study, conducted at a referral center for weight management, retrospectively collected data on the use of semaglutide for adults with overweight or obesity between January 1, 2021, and March 15, 2022, with a follow-up of up to 6 months.
Summary · context
A total of 408 patients with a body mass index (BMI) of 27 or more were prescribed weekly semaglutide subcutaneous injections for 3 months or more.
Show in the study text Report a problemFND-3612165204
05HumanObservational studyEfficacy outcome
In adults with overweight or obesity followed for 6 months on semaglutide, 23.5% achieved weight loss of 15% or more.
In plain wordsIn adults with overweight or obesity, 23.5% of people on semaglutide lost at least 15% of body weight after 6 months.
Peptide
Semaglutide
Outcome
Not applicableWeight loss of 15% or more at 6 months
Study
n = 102
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.7 mg or 2.4 mg weekly · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Patients with weight loss >=15%
23.5%
6 months
Source sentences
Summary
24 (23.5%) achieved weight loss of 15% or more,
2 context sentences(design, population, supporting numbers)
Summary · context
This cohort study, conducted at a referral center for weight management, retrospectively collected data on the use of semaglutide for adults with overweight or obesity between January 1, 2021, and March 15, 2022, with a follow-up of up to 6 months.
Summary · context
A total of 408 patients with a body mass index (BMI) of 27 or more were prescribed weekly semaglutide subcutaneous injections for 3 months or more.
Show in the study text Report a problemFND-3612165205
06HumanObservational studyEfficacy outcome
In adults with overweight or obesity followed for 6 months on semaglutide, 7.8% achieved weight loss of 20% or more.
In plain wordsIn adults with overweight or obesity, 7.8% of people on semaglutide lost at least 20% of body weight after 6 months.
Peptide
Semaglutide
Outcome
Not applicableWeight loss of 20% or more at 6 months
Study
n = 102
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.7 mg or 2.4 mg weekly · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Patients with weight loss >=20%
7.8%
6 months
Source sentences
Summary
8 (7.8%) achieved weight loss of 20% or more.
2 context sentences(design, population, supporting numbers)
Summary · context
This cohort study, conducted at a referral center for weight management, retrospectively collected data on the use of semaglutide for adults with overweight or obesity between January 1, 2021, and March 15, 2022, with a follow-up of up to 6 months.
Summary · context
A total of 408 patients with a body mass index (BMI) of 27 or more were prescribed weekly semaglutide subcutaneous injections for 3 months or more.
Show in the study text Report a problemFND-3612165206
07HumanObservational studyEfficacy outcome
In adults with overweight or obesity, semaglutide-treated patients with type 2 diabetes lost less weight at 3 months (3.9%) than those without type 2 diabetes (6.3%).
In plain wordsIn adults on semaglutide, people with type 2 diabetes lost less weight after 3 months than people without type 2 diabetes.
Peptide
Semaglutide
Outcome
Not applicableWeight loss at 3 months, with versus without type 2 diabetes
Study
n: not reported in source
Comparator
Patients without type 2 diabetes
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.7 mg or 2.4 mg weekly · subcutaneous · 3 monthsAs given in this study (human).
Measurements
Weight loss, with type 2 diabetes
3.9%
3 months
Weight loss, without type 2 diabetes
6.3%
3 months
Source sentences
Summary
Patients with type 2 diabetes had a lower mean (SD) percentage weight loss at 3 and 6 months compared with those without type 2 diabetes: 3.9% (3.1%) vs 6.3% (3.7%) at 3 months (P = .001)
2 context sentences(design, population, supporting numbers)
Summary · context
This cohort study, conducted at a referral center for weight management, retrospectively collected data on the use of semaglutide for adults with overweight or obesity between January 1, 2021, and March 15, 2022, with a follow-up of up to 6 months.
Summary · context
A total of 408 patients with a body mass index (BMI) of 27 or more were prescribed weekly semaglutide subcutaneous injections for 3 months or more.
Show in the study text Report a problemFND-3612165207
08HumanObservational studyEfficacy outcome
In adults with overweight or obesity, semaglutide-treated patients with type 2 diabetes lost less weight at 6 months (7.2%) than those without type 2 diabetes (11.8%).
In plain wordsIn adults on semaglutide, people with type 2 diabetes lost less weight after 6 months than people without type 2 diabetes.
Peptide
Semaglutide
Outcome
Not applicableWeight loss at 6 months, with versus without type 2 diabetes
Study
n: not reported in source
Comparator
Patients without type 2 diabetes
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Studied dose
1.7 mg or 2.4 mg weekly · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Weight loss, with type 2 diabetes
7.2%
6 months
Weight loss, without type 2 diabetes
11.8%
6 months
Source sentences
Summary
Patients with type 2 diabetes had a lower mean (SD) percentage weight loss at 3 and 6 months compared with those without type 2 diabetes: 3.9% (3.1%) vs 6.3% (3.7%) at 3 months (P = .001) and 7.2% (6.3%) vs 11.8% (5.3%) at 6 months (P = .005)
2 context sentences(design, population, supporting numbers)
Summary · context
This cohort study, conducted at a referral center for weight management, retrospectively collected data on the use of semaglutide for adults with overweight or obesity between January 1, 2021, and March 15, 2022, with a follow-up of up to 6 months.
Summary · context
A total of 408 patients with a body mass index (BMI) of 27 or more were prescribed weekly semaglutide subcutaneous injections for 3 months or more.
Show in the study text Report a problemFND-3612165208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.